Which adrenergic drug is specifically indicated for treating overactive bladder?

Mirabegron is specifically indicated for treating overactive bladder due to its mechanism of action as a β3-adrenergic agonist. By stimulating β3-adrenergic receptors in the detrusor muscle of the bladder, Mirabegron promotes relaxation of this muscle, thereby increasing bladder capacity and reducing the frequency of involuntary contractions that lead to urgency and urinary incontinence. This targeted action makes it distinct among adrenergic drugs, as it directly addresses the symptoms associated with overactive bladder without causing the side effects typically seen with first-generation anticholinergic medications.

In contrast, epinephrine is a non-selective adrenergic agonist that activates both α and β receptors, primarily used in emergencies such as anaphylaxis or cardiac arrest, not for bladder conditions. Dobutamine is primarily a β1-adrenergic agonist used in heart failure and acute heart conditions; it does not have an established role in managing bladder function. Phenylephrine is an α1-adrenergic agonist commonly used as a decongestant and for raising blood pressure, rather than for bladder issues. Therefore, Mirabegron stands out as the appropriate choice for its specific therapeutic role in treating overactive bladder